BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23940221)

  • 1. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
    Heerema NA; Carroll AJ; Devidas M; Loh ML; Borowitz MJ; Gastier-Foster JM; Larsen EC; Mattano LA; Maloney KW; Willman CL; Wood BL; Winick NJ; Carroll WL; Hunger SP; Raetz EA
    J Clin Oncol; 2013 Sep; 31(27):3397-402. PubMed ID: 23940221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
    Moorman AV; Robinson H; Schwab C; Richards SM; Hancock J; Mitchell CD; Goulden N; Vora A; Harrison CJ
    J Clin Oncol; 2013 Sep; 31(27):3389-96. PubMed ID: 23940220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
    Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
    Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review.
    Johnson RC; Weinberg OK; Cascio MJ; Dahl GV; Mitton BA; Silverman LB; Cherry AM; Arber DA; Ohgami RS
    Am J Clin Pathol; 2015 Jul; 144(1):103-12. PubMed ID: 26071468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
    Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
    J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is intrachromosomal amplification of chromosome 21 (iAMP21) always intrachromosomal?
    Tsuchiya KD; Davis B; Gardner RA
    Cancer Genet; 2017 Dec; 218-219():10-14. PubMed ID: 29153092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of unusual iAMP21 B-lymphoblastic leukemia (iAMP21-ALL) from the Mayo Clinic and Children's Oncology Group.
    Koleilat A; Smadbeck JB; Zepeda-Mendoza CJ; Williamson CM; Pitel BA; Golden CL; Xu X; Greipp PT; Ketterling RP; Hoppman NL; Peterson JF; Harrison CJ; Akkari YMN; Tsuchiya KD; Shago M; Baughn LB
    Genes Chromosomes Cancer; 2022 Dec; 61(12):710-719. PubMed ID: 35771717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.
    Harrison CJ; Moorman AV; Schwab C; Carroll AJ; Raetz EA; Devidas M; Strehl S; Nebral K; Harbott J; Teigler-Schlegel A; Zimmerman M; Dastuge N; Baruchel A; Soulier J; Auclerc MF; Attarbaschi A; Mann G; Stark B; Cazzaniga G; Chilton L; Vandenberghe P; Forestier E; Haltrich I; Raimondi SC; Parihar M; Bourquin JP; Tchinda J; Haferlach C; Vora A; Hunger SP; Heerema NA; Haas OA;
    Leukemia; 2014 May; 28(5):1015-21. PubMed ID: 24166298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and Clinical Characteristics of Intrachromosomal Amplification of Chromosome 21 in Korean Childhood B-lineage Acute Lymphoblastic Leukemia.
    Kim J; Lyu CJ; Shin S; Lee ST; Choi JR
    Ann Lab Med; 2016 Sep; 36(5):475-80. PubMed ID: 27374714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
    Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
    Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
    Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease.
    Harrison CJ
    Blood; 2015 Feb; 125(9):1383-6. PubMed ID: 25608562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
    Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
    Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
    [No Abstract]   [Full Text] [Related]  

  • 16. B-Cell Acute Lymphoblastic Leukemia with iAMP21 in a Patient with Constitutional Ring Chromosome 21.
    Baloda V; Aggarwal N; Rosado FG; Mackey S; Felker J; Yatsenko SA
    Cytogenet Genome Res; 2022; 162(5):231-236. PubMed ID: 36502796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
    Zak T; Gao J; Behdad A; Mehta J; Altman JK; Ji P; Lu X; Sukhanova M
    Leuk Lymphoma; 2022 Dec; 63(13):3200-3207. PubMed ID: 35995457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic homozygous loss of SH2B3, and a non-Robertsonian translocation t(15;21)(q25.3;q22.1) with NTRK3 rearrangement, in an adolescent with progenitor B-cell acute lymphoblastic leukemia with the iAMP21.
    Capela de Matos RR; Othman M; Ferreira GM; Monteso K; de Souza MT; Rouxinol M; Melo JB; Carreira IM; Abdelhay E; Liehr T; Ribeiro RC; Silva M
    Cancer Genet; 2022 Apr; 262-263():16-22. PubMed ID: 34974289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
    Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.